Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 27;17(5):106182.
doi: 10.4254/wjh.v17.i5.106182.

Sarcopenia and frailty: An in-depth analysis of the pathophysiology and effect on liver transplant candidates

Affiliations
Review

Sarcopenia and frailty: An in-depth analysis of the pathophysiology and effect on liver transplant candidates

Grigorios Christodoulidis et al. World J Hepatol. .

Abstract

Cirrhosis represents the end stage of chronic liver disease, significantly reducing life expectancy as it progresses from a compensated to a decompensated state, leading to serious complications. Recent improvements in medical treatment have created a shift in cirrhosis management. Various causes, including hepatitis viruses, alcohol consumption, and fatty liver disease, contribute to cirrhosis and are closely linked to liver cancer. The disease develops through hepatocyte necrosis and regeneration, resulting in fibrosis and sinusoidal capillarization, leading to portal hypertension and complications such as ascites, hepatic encephalopathy, and organ dysfunction. Cirrhosis also holds an increased risk of hepatocellular carcinoma. Diagnosing cirrhosis involves assessing fibrosis scores through blood tests and measuring liver stiffness through elastography. Liver transplantation is the definitive treatment for end-stage liver disease and acute liver failure.

Keywords: Artificial intelligence; Chronic liver disease; Cirrhosis; End-stage liver disease; Frailty; Liver fibrosis; Liver transplant; Muscle mass loss; Pathophysiology; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Similar articles

References

    1. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. - PMC - PubMed
    1. Dhaliwal A, Williams, FR, El-sherif, O, Armstrong MJ. Sarcopenia in Liver Transplantation: an Update. Curr Hepatology Rep. 2020;19:128–137.
    1. Liu X, Hao Q, Hou L, Xia X, Zhao W, Zhang Y, Ge M, Liu Y, Zuo Z, Yue J, Dong B. Ethnic Groups Differences in the Prevalence of Sarcopenia Using the AWGS Criteria. J Nutr Health Aging. 2020;24:665–671. - PubMed
    1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. - PMC - PubMed
    1. Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75 Suppl 1:S147–S162. - PMC - PubMed

LinkOut - more resources